<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118522</article-id><article-id pub-id-type="publisher-id">ACM-44695</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_27863544.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  前列地尔联合罂粟碱在IC保守治疗中的临床价值及Nomogram的构建
  Clinical Value of Alprostadil Combined with Popaverine in Conservative Treatment of Ischemic Colitis and Establishment of a Nomogram Prediction Model
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>凯凯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>柳</surname><given-names>维林</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>江</surname><given-names>秀丽</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>盛</surname><given-names>延钦</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>曦</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>荆</surname><given-names>丽宏</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>小雷</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff5"><addr-line>青岛优抚医院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff4"><addr-line>青岛大学附属医院市南院区，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛城阳区疾病预防控制中心，山东 青岛</addr-line></aff><aff id="aff6"><addr-line>青岛大学附属医院平度院区，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3574</fpage><lpage>3584</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨影响缺血性结肠炎患者保守治疗效果的相关因素，评估前列地尔联合罂粟碱在保守治疗中的临床价值，并构建保守治疗效果的个体化列线图预测模型(Nomogram)。方法：本研究共选取2018年1月至2021年1月于青岛大学附属医院收治的98例缺血性结肠炎患者，随机分为观察组和对照组，对照组给予常规保守治疗，观察组在其基础上加用前列地尔联合罂粟碱治疗，主要研究终点是IC患者保守治疗一周后的效果；分析影响保守治疗效果的相关因素，应用R软件绘制基于Logistic回归分析保守治疗效果的预测模型，绘制ROC曲线评估模型的区分度，绘制校准曲线评估模型的校准度。结果：保守治疗一周后，观察组治疗有效率为93.88%，对照组治疗有效率71.43%，差异有统计学意义，观察组中腹痛消失的时间为3.24 &#177; 1.73 d，腹泻消失的时间为2.42 &#177; 1.08 d，大便潜血阳性消失的时间为3.92 &#177; 1.15 d，住院时间为9.80 &#177; 2.80 d，均小于对照组；将治疗效果作为结局变量，单因素分析显示治疗有效组入院白细胞计数、中性粒细胞百分比，中性粒细胞计数、C反应蛋白、降钙素原水平均低于无效组，差异有统计学意义(P &lt; 0.05)；有效组中联合应用前列地尔及罂粟碱患者所占的比例(56.79%)大于无效组(17.65%)，且差异有统计学意义(P &lt; 0.05)；多因素Logistic回归分析显示，入院CRP，PCT水平以及治疗方式是保守治疗有效率的独立影响因素(P &lt; 0.05)。构建保守治疗有效率的列线图预测模型，ROC曲线显示模型具有良好的区分度(AUC = 0.963, (95%CI: 0.928~0.998))，校准曲线显示模型具有良好的校准度。结论：前列地尔联合罂粟碱缩短了缺血性结肠炎患者临床症状的缓解时间及住院时间，增加了治疗有效率，且无严重不良反应，可在IC患者中安全应用，本研究构建的列线图模型可个体化预测IC患者保守治疗的效果，帮助医生和患者选择合理的治疗决策。
   Objective: To explore the factors affecting conservative treatment in patients with ischemic colitis, assess the value of leading alprostadil combined with popaverine in conservative treatment and construct an individualized linographic prediction model for the effect of conservative treatment. Methods: This study included 98 patients with ischemic colitis admitted from the Affiliated Hospital of Qingdao University from January 2018 to January 2021, who were randomly divided into observation group and control group. The control Group was given routine conservative treatment, and the observation group was additionally treated with alprostadil combined with papaverine. The primary endpoint was the effect after 1 week of conservative treatment in patients with IC. Independent-sample T test was used to compare the measurement data, &#178; test was used to compare the counting data. R software was used to drawn the prediction model based on logistic regression analysis of conservative treatment effect. Calibration curve was drawn to analyze the calibration degree of the model, and ROC curve was drawn to evaluate the discrimination degree of the model. Results: After 1 week of conservative treatment, the effective rate of the observation group was 93.88%, and that of the control group was 71.43%, the difference was statistically significant. In the observation group, the disappearance time of abdominal pain was 3.24 &#177; 1.73 days, the disappearance time of diarrhea was 2.42 &#177; 1.08 days, the disappearance time of stool occult blood test positive was 3.92 &#177; 1.15 days, and the hospitalization time was 9.80 &#177; 2.80 days, less than that in the control group. Univariate analysis showed that admission WBC, NE, NE%, CRP and PCT in the effective group were lower than those in the ineffective group, the difference was statistically significant (P &lt; 0.05). Multivariate logistic regression analysis showed that admission CRP, PCT and treatment mode were independent influencing factors of conservative treatment efficiency (P &lt; 0.05). Nomogram prediction model of conservative treatment efficiency was constructed. The ROC curve showed that the model had good discrimination (AUC = 0.963, (95%CI: 0.928~0.998)), and the calibration curve showed that the model had good calibration. Conclusion: Alprostadil combined with papaverine can shorten the remission time of clinical symptoms and hospitalization time of patients with IC, increase the treatment efficiency, and have no serious adverse reactions, which can be safely applied in patients with IC. The nomogram model constructed in this study can predict the effect of conservative treatment of patients with IC individually, and help doctors and patients choose reasonable treatment decisions.
 
</p></abstract><kwd-group><kwd>缺血性结肠，C-反应蛋白，降钙素原，前列地尔，罂粟碱, Ischemic Colitis</kwd><kwd> C-Reactive Protein</kwd><kwd> Procalcitonin</kwd><kwd> Alprostadil</kwd><kwd> Popaverine</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨影响缺血性结肠炎患者保守治疗效果的相关因素，评估前列地尔联合罂粟碱在保守治疗中的临床价值，并构建保守治疗效果的个体化列线图预测模型(Nomogram)。方法：本研究共选取2018年1月至2021年1月于青岛大学附属医院收治的98例缺血性结肠炎患者，随机分为观察组和对照组，对照组给予常规保守治疗，观察组在其基础上加用前列地尔联合罂粟碱治疗，主要研究终点是IC患者保守治疗一周后的效果；分析影响保守治疗效果的相关因素，应用R软件绘制基于Logistic回归分析保守治疗效果的预测模型，绘制ROC曲线评估模型的区分度，绘制校准曲线评估模型的校准度。结果：保守治疗一周后，观察组治疗有效率为93.88%，对照组治疗有效率71.43%，差异有统计学意义，观察组中腹痛消失的时间为3.24 &#177; 1.73 d，腹泻消失的时间为2.42 &#177; 1.08 d，大便潜血阳性消失的时间为3.92 &#177; 1.15 d，住院时间为9.80 &#177; 2.80 d，均小于对照组；将治疗效果作为结局变量，单因素分析显示治疗有效组入院白细胞计数、中性粒细胞百分比，中性粒细胞计数、C反应蛋白、降钙素原水平均低于无效组，差异有统计学意义(P &lt; 0.05)；有效组中联合应用前列地尔及罂粟碱患者所占的比例(56.79%)大于无效组(17.65%)，且差异有统计学意义(P &lt; 0.05)；多因素Logistic回归分析显示，入院CRP，PCT水平以及治疗方式是保守治疗有效率的独立影响因素(P &lt; 0.05)。构建保守治疗有效率的列线图预测模型，ROC曲线显示模型具有良好的区分度(AUC = 0.963, (95%CI: 0.928~0.998))，校准曲线显示模型具有良好的校准度。结论：前列地尔联合罂粟碱缩短了缺血性结肠炎患者临床症状的缓解时间及住院时间，增加了治疗有效率，且无严重不良反应，可在IC患者中安全应用，本研究构建的列线图模型可个体化预测IC患者保守治疗的效果，帮助医生和患者选择合理的治疗决策。</p></sec><sec id="s2"><title>关键词</title><p>缺血性结肠，C-反应蛋白，降钙素原，前列地尔，罂粟碱</p></sec><sec id="s3"><title>Clinical Value of Alprostadil Combined with Popaverine in Conservative Treatment of Ischemic Colitis and Establishment of a Nomogram Prediction Model<sup> </sup></title><p>Kaikai Zhang<sup>1</sup>, Weilin Liu<sup>2</sup>, Xiuli Jiang<sup>3</sup>, Yanqin Sheng<sup>4</sup>, Xi Chen<sup>5</sup>, Lihong Jing<sup>5</sup>, Xiaolei Liu<sup>5*</sup></p><p><sup>1</sup>The Affiliated Hospital Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Qingdao Chengyang District Center for Disease Control and Prevention, Qingdao Shandong</p><p><sup>3</sup>Shinan District, The Affiliated Hospital Qingdao University, Qingdao Shandong</p><p><sup>4</sup>Qingdao Youfu Hospital, Qingdao Shandong</p><p><sup>5</sup>Pingdu District, The Affiliated Hospital Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/39-1572464x5_hanspub.png?20210823170314773" /></p><p>Received: Jul. 18<sup>th</sup>, 2021; accepted: Aug. 16<sup>th</sup>, 2021; published: Aug. 23<sup>rd</sup>, 2021</p><p><img src="//html.hanspub.org/file/39-1572464x6_hanspub.png?20210823170314773" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the factors affecting conservative treatment in patients with ischemic colitis, assess the value of leading alprostadil combined with popaverine in conservative treatment and construct an individualized linographic prediction model for the effect of conservative treatment. Methods: This study included 98 patients with ischemic colitis admitted from the Affiliated Hospital of Qingdao University from January 2018 to January 2021, who were randomly divided into observation group and control group. The control Group was given routine conservative treatment, and the observation group was additionally treated with alprostadil combined with papaverine. The primary endpoint was the effect after 1 week of conservative treatment in patients with IC. Independent-sample T test was used to compare the measurement data, c&#178; test was used to compare the counting data. R software was used to drawn the prediction model based on logistic regression analysis of conservative treatment effect. Calibration curve was drawn to analyze the calibration degree of the model, and ROC curve was drawn to evaluate the discrimination degree of the model. Results: After 1 week of conservative treatment, the effective rate of the observation group was 93.88%, and that of the control group was 71.43%, the difference was statistically significant. In the observation group, the disappearance time of abdominal pain was 3.24 &#177; 1.73 days, the disappearance time of diarrhea was 2.42 &#177; 1.08 days, the disappearance time of stool occult blood test positive was 3.92 &#177; 1.15 days, and the hospitalization time was 9.80 &#177; 2.80 days, less than that in the control group. Univariate analysis showed that admission WBC, NE, NE%, CRP and PCT in the effective group were lower than those in the ineffective group, the difference was statistically significant (P &lt; 0.05). Multivariate logistic regression analysis showed that admission CRP, PCT and treatment mode were independent influencing factors of conservative treatment efficiency (P &lt; 0.05). Nomogram prediction model of conservative treatment efficiency was constructed. The ROC curve showed that the model had good discrimination (AUC = 0.963, (95%CI: 0.928~0.998)), and the calibration curve showed that the model had good calibration. Conclusion: Alprostadil combined with papaverine can shorten the remission time of clinical symptoms and hospitalization time of patients with IC, increase the treatment efficiency, and have no serious adverse reactions, which can be safely applied in patients with IC. The nomogram model constructed in this study can predict the effect of conservative treatment of patients with IC individually, and help doctors and patients choose reasonable treatment decisions.</p><p>Keywords:Ischemic Colitis, C-Reactive Protein, Procalcitonin, Alprostadil, Popaverine</p><disp-formula id="hanspub.44695-formula8"><graphic xlink:href="//html.hanspub.org/file/39-1572464x7_hanspub.png?20210823170314773"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/39-1572464x8_hanspub.png?20210823170314773" /> <img src="//html.hanspub.org/file/39-1572464x9_hanspub.png?20210823170314773" /></p></sec><sec id="s5"><title>1. 引言</title><p>缺血性结肠炎(ischemic colitis, IC)，是由于结肠血液供应不足或再灌注损伤所导致的肠道不同程度组织坏死和一系列症状的疾病 [<xref ref-type="bibr" rid="hanspub.44695-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref2">2</xref>]。IC发病年龄多在50岁以上，是急性下消化道出血最常见的原因之一，以女性多见 [<xref ref-type="bibr" rid="hanspub.44695-ref3">3</xref>]，半数以上的IC患者伴有高血压、动脉硬化、冠心病和糖尿病等基础疾病 [<xref ref-type="bibr" rid="hanspub.44695-ref4">4</xref>]。IC患者早期多以腹痛、腹泻、便血等非特异性消化道症状为主，严重者可出现腹膜刺激征、肠穿孔、肠坏死甚至危及生命 [<xref ref-type="bibr" rid="hanspub.44695-ref5">5</xref>]。随着我国老龄化人口的增多，电子结肠镜、CT (Computed Tomography Scanner System)等辅助检查的普及，以及对疾病认识水平的提高，IC发病率呈现出逐年升高的趋势 [<xref ref-type="bibr" rid="hanspub.44695-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref7">7</xref>]。临床上对于IC患者的治疗多以积极处理基础疾病、禁食、抗生素抗感染、维持水电解质平衡，以及改善微循环等保守治疗为主 [<xref ref-type="bibr" rid="hanspub.44695-ref1">1</xref>]。近年来前列地尔及罂粟碱在缺血性疾病的治疗中得到了广泛的应用，但两者联合应用治疗缺血性结肠炎的研究相对较少。本研究旨在探讨前列地尔联合罂粟碱在IC患者保守治疗中的价值，并构建可视化列线图预测模型。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><sec id="s6_1_1"><title>2.1.1. 研究对象</title><p>选取2018年1月至2021年1月我院收治的98例缺血性结肠炎患者，应用随机化分组的方法分为观察组和对照组，观察组49人，年龄42~88岁，平均(63.35 &#177; 5.34)岁，其中男性17例(34.7%)，女性32例(65.3%)，对照组49人，年龄46~83岁，平均(62.72 &#177; 5.21)岁，其中男性18例(36.7%)，女性31例(63.3%)。两组患者发病部位及一般资料比较差异无统计学意义(P &lt; 0.05)。在治疗期间无临床死亡患者。本研究经青岛大学附属医院医学伦理委员会审核批准，研究对象及家属知情同意并签署知情同意书。</p></sec><sec id="s6_1_2"><title>2.1.2. 纳入及排除标准</title><p>1) 纳入标准</p><p>a) 年龄大于40岁；</p><p>b) 经影像学或结肠镜检查确诊为IC的患者；</p><p>c) 临床资料完善。</p><p>2) 排除标准</p><p>a) 年龄小于40岁；</p><p>b) 不能与其他炎症性肠病鉴别的患者；</p><p>c) 因内疝、外伤、肠扭转、肿瘤等因素引起结肠缺血的患者；</p><p>d) 出现穿孔、腹膜炎等并发症的重症IC患者；</p><p>e) 临床资料不完善。</p></sec></sec><sec id="s6_2"><title>2.2. 治疗方法</title><p>两组均进行常规保守治疗，主要包括以下几个方面：1) 较重型患者早期禁食，轻型患者可流质饮食并使用微生态制剂，如酪酸梭菌活菌胶囊等；2) 静脉营养支持、维持水电解质平衡；3) 应用头孢菌素联合奥硝唑抗感染治疗；4) 积极治疗心血管系统原发病，停用血管收缩药(肾上腺素、多巴胺等)；5) 应用肛管排气或灌肠以缓解结肠扩张；6) 禁止使用止血类药物。此外观察组在以上基础上联合应用前列地尔(前列地尔10微克加生理盐水稀释后缓慢静推，Qd)和罂粟碱(30毫克加生理盐水稀释后肌肉注射，Tid)，观察组和对照组的治疗周期均为7天。</p></sec><sec id="s6_3"><title>2.3. 相关检测指标</title><p>观察患者腹痛、腹泻、大便潜血阳性等症状消失的时间及出院时间；记录患者入院(治疗前)及治疗7天后炎症指标包括白细胞计数(White blood cell count, WBC)、中性粒细胞计数(Neutrophil, NE)、中性粒细胞百分比(NE%)、C-反应蛋白(C-reactive protein, CRP)、降钙素原(Procalcitonin, PCT)结果；记录患者入院(治疗前)及治疗7天后血清D-二聚体(D-Dimer)结果。</p></sec><sec id="s6_4"><title>2.4. 疗效判定标准</title><p>疗效判定标准如下，1) 有效：患者腹痛、腹泻、便血等临床症状消失，炎症指标恢复正常或明显下降，行CT检查显示肠壁水肿增厚较前明显好转且出院2周后门诊复查无复发症状；2) 显效：患者腹痛、腹泻、便血等临床症状明显缓解，炎症指标下降，行CT检查显示肠壁水肿增厚较前好转且出院2周后门诊复查无复发症状；3) 无效：经以上治疗后患者腹痛、腹泻、便血等症状未见缓解甚至症状恶化需行急症手术治疗 [<xref ref-type="bibr" rid="hanspub.44695-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref8">8</xref>]。记录治疗的总有效率和相关不良反应。</p></sec><sec id="s6_5"><title>2.5. 统计学方法</title><p>应用SPSS23.0软件和R软件进行统计学分析，分析各组患者的一般资料、临床表现、实验室检查、治疗方案、疾病转归。呈正态分布的计量资料以 x &#175; &#177; s描述，呈偏态分布的计量资料以中位数(范围)表示，两组间比较采用独立样本t检验；计数资料以例(%)表示，组间比较采用χ<sup>2</sup>检验，以P &lt; 0.05 (双侧检验)为差异有统计学意义。应用R软件绘制治疗有效率的列线图模型并绘制校正曲线，评估模型的校准度，反应模型评估治疗有效率的能力；绘制ROC曲线用于判断模型的区分度，曲线下面积(AUC) &gt; 0.75认为模型具有良好的区分度。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 临床症状</title><p>将观察组及对照组经治疗后临床症状消失的时间以及总住院时间进行对比。观察组腹痛消失的时间为3.24 &#177; 1.73 d，腹泻消失的时间为2.42 &#177; 1.08 d，大便潜血阳性消失的时间为3.92 &#177; 1.15 d，住院时间为9.80 &#177; 2.80 d，均小于对照组(表1)。</p></sec><sec id="s7_2"><title>3.2. 检验指标</title><p>将两组患者治疗前后检验指标进行对比。治疗前，观察组及对照组白细胞计数、中性粒细胞计数、中性粒细胞百分比、C-反应蛋白、降钙素原差异均无统计学意义；治疗7天后观察组白细胞计数、中性粒细胞计数、中性粒细胞百分比、C-反应蛋白、降钙素原均低于对照组，且白细胞计数、C反应蛋白差异有统计学意义(表2)；将两组患者治疗前后D二聚体结果进行对比，治疗前两组患者D二聚体差异无统计学意义，治疗7天后，观察组患者D二聚体水平低于对照组且差异有统计学意义(表2)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical symptom duration and hospital stay between the two groups (d, x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >腹痛</th><th align="center" valign="middle" >腹泻</th><th align="center" valign="middle" >大便隐血</th><th align="center" valign="middle" >住院时间</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >3.24 &#177; 1.73</td><td align="center" valign="middle" >2.42 &#177; 1.08</td><td align="center" valign="middle" >3.92 &#177; 1.15</td><td align="center" valign="middle" >9.80 &#177; 2.80</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >4.55 &#177; 2.82</td><td align="center" valign="middle" >3.95 &#177; 1.76</td><td align="center" valign="middle" >5.05 &#177; 1.66</td><td align="center" valign="middle" >13.75 &#177; 3.22</td></tr></tbody></table></table-wrap><p>表1. 两组患者临床症状持续时间及住院时间比较(d, x &#175; &#177; s)</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of inspection results of two groups before and after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >临床特征</th><th align="center" valign="middle" >观察组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle"  rowspan="5"  >治疗前</td><td align="center" valign="middle" >白细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" >11.45 &#177; 3.11</td><td align="center" valign="middle" >11.87 &#177; 3.38</td><td align="center" valign="middle" >0.464</td></tr><tr><td align="center" valign="middle" >中性粒细胞百分比(%)</td><td align="center" valign="middle" >83.37 &#177; 5.24</td><td align="center" valign="middle" >82.08 &#177; 7.38</td><td align="center" valign="middle" >0.321</td></tr><tr><td align="center" valign="middle" >C-反应蛋白(mg/L)</td><td align="center" valign="middle" >34.91 &#177; 30.77</td><td align="center" valign="middle" >38.33 &#177; 35.84</td><td align="center" valign="middle" >0.614</td></tr><tr><td align="center" valign="middle" >降钙素原(ng/mL)</td><td align="center" valign="middle" >0.27 &#177; 0.28</td><td align="center" valign="middle" >0.31 &#177; 0.35</td><td align="center" valign="middle" >0.550</td></tr><tr><td align="center" valign="middle" >D-二聚体(ng/mL)</td><td align="center" valign="middle" >2.76 &#177; 2.93</td><td align="center" valign="middle" >2.55 &#177; 2.63</td><td align="center" valign="middle" >0.622</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >治疗后</td><td align="center" valign="middle" >白细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" >6.09 &#177; 2.16</td><td align="center" valign="middle" >7.83 &#177; 4.75</td><td align="center" valign="middle" >0.022</td></tr><tr><td align="center" valign="middle" >中性粒细胞百分比(%)</td><td align="center" valign="middle" >60.18 &#177; 10.73</td><td align="center" valign="middle" >61.54 &#177; 14.65</td><td align="center" valign="middle" >0.601</td></tr><tr><td align="center" valign="middle" >C-反应蛋白(mg/L)</td><td align="center" valign="middle" >9.21 &#177; 27.72</td><td align="center" valign="middle" >27.82 &#177; 52.89</td><td align="center" valign="middle" >0.032</td></tr><tr><td align="center" valign="middle" >降钙素原(ng/mL)</td><td align="center" valign="middle" >0.09 &#177; 0.32</td><td align="center" valign="middle" >0.25 &#177; 0.67</td><td align="center" valign="middle" >0.068</td></tr><tr><td align="center" valign="middle" >D-二聚体(mg/L)</td><td align="center" valign="middle" >0.58 &#177; 1.47</td><td align="center" valign="middle" >1.14 &#177; 2.13</td><td align="center" valign="middle" >0.043</td></tr></tbody></table></table-wrap><p>表2. 两组患者治疗前后检验结果比较</p></sec><sec id="s7_3"><title>3.3. 治疗效果</title><p>将2组治疗效果进行对比，观察组49人经上述治疗7天后27人症状消失，19人症状较前缓解，3人症状未见明显变化，其中1人症状加重行急症手术，无临床死亡病例，治疗有效率为93.88%；对照组49人经上述治疗7天后21人症状消失，14人症状缓解，14人症状未见明显变化，其中3人行急症手术，无临床死亡病例，治疗有效率为71.43%，两组治疗效果差异有统计学意义(表3)；两组患者治疗的总有效率为82.65%。以上患者均未见严重不良反应。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of the overall efficacy between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >有效率(%)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >93.88</td><td align="center" valign="middle"  rowspan="2"  >0.003</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >71.43</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >82.65</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 两组患者总体疗效对比(例)</p></sec><sec id="s7_4"><title>3.4. IC患者保守治疗有效率的预测模型建立及评价</title><p>将治疗效果作为结局变量，对选取的临床变量进行单因素分析显示，有效组入院白细胞计数、中性粒细胞百分比，中性粒细胞计数、C反应蛋白、降钙素原水平均低于无效组，差异有统计学意义；有效组中联合应用前列地尔及罂粟碱患者所占的比例大于无效组，且差异有统计学意义(表4)。制作入院WBC、CRP、PCT三个变量的ROC曲线(图1)，并计算其敏感性、特异性及最佳截断值(表5)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Results of single factor analysis on the effective rate of conservative treatment in patients with I</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >相关因素</th><th align="center" valign="middle"  colspan="2"  >治疗效果</th><th align="center" valign="middle"  rowspan="2"  >c<sup>2</sup>/Z值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >有效</td><td align="center" valign="middle" >无效</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >6</td><td align="center" valign="middle"  rowspan="2"  >0.018</td><td align="center" valign="middle"  rowspan="2"  >0.892</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤65岁</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >5</td><td align="center" valign="middle"  rowspan="2"  >1.518</td><td align="center" valign="middle"  rowspan="2"  >0.218</td></tr><tr><td align="center" valign="middle" >&gt;65岁</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >12</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤24</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >7</td><td align="center" valign="middle"  rowspan="2"  >0.186</td><td align="center" valign="middle"  rowspan="2"  >0.666</td></tr><tr><td align="center" valign="middle" >&gt;24</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >治疗组别(例)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >3</td><td align="center" valign="middle"  rowspan="2"  >8.611</td><td align="center" valign="middle"  rowspan="2"  >0.003</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle" >白细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" >11.136 &#177; 2.715</td><td align="center" valign="middle" >14.153 &#177; 1.764</td><td align="center" valign="middle" >−3.017</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >中性粒细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" >8.632 &#177; 1.375</td><td align="center" valign="middle" >11.437 &#177; 1.875</td><td align="center" valign="middle" >−3.592</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >中性粒细胞百分比(%)</td><td align="center" valign="middle" >81.785 &#177; 6.327</td><td align="center" valign="middle" >87.177 &#177; 4.763</td><td align="center" valign="middle" >−5.391</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >红细胞计数(10<sup>12</sup>/L)</td><td align="center" valign="middle" >4.102 &#177; 0.443</td><td align="center" valign="middle" >3.899 &#177; 0.578</td><td align="center" valign="middle" >0.125</td><td align="center" valign="middle" >0.108</td></tr><tr><td align="center" valign="middle" >血红蛋白(g/L)</td><td align="center" valign="middle" >128.938 &#177; 14.717</td><td align="center" valign="middle" >123.882 &#177; 17.660</td><td align="center" valign="middle" >4.067</td><td align="center" valign="middle" >0.217</td></tr><tr><td align="center" valign="middle" >血小板计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" >318.765 &#177; 62.632</td><td align="center" valign="middle" >330.015 &#177; 64.740</td><td align="center" valign="middle" >17.178</td><td align="center" valign="middle" >0.514</td></tr><tr><td align="center" valign="middle" >C-反应蛋白(mg/L)</td><td align="center" valign="middle" >27.271 &#177; 23.651</td><td align="center" valign="middle" >81.166 &#177; 36.951</td><td align="center" valign="middle" >7.026</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >降钙素原(ng/mL)</td><td align="center" valign="middle" >0.191 &#177; 0.222</td><td align="center" valign="middle" >0.765 &#177; 0.279</td><td align="center" valign="middle" >0.621</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >D-二聚体(mg/L)</td><td align="center" valign="middle" >1.817 &#177; 2.163</td><td align="center" valign="middle" >2.772 &#177; 4.384</td><td align="center" valign="middle" >0.273</td><td align="center" valign="middle" >0.075</td></tr></tbody></table></table-wrap><p>表4. 影响IC患者保守治疗有效率的单因素分析结果</p><p>图1. IC患者治疗前WBC、CRP、PCT的ROC曲线</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Cut-off value distribution of ROC curv</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >检验指标</th><th align="center" valign="middle" >Cut-off值</th><th align="center" valign="middle" >敏感性</th><th align="center" valign="middle" >特异性</th><th align="center" valign="middle" >AUC</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >白细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" >12.450</td><td align="center" valign="middle" >0.882</td><td align="center" valign="middle" >0.728</td><td align="center" valign="middle" >0.851</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >C-反应蛋白(mg/L)</td><td align="center" valign="middle" >56.190</td><td align="center" valign="middle" >0.942</td><td align="center" valign="middle" >0.767</td><td align="center" valign="middle" >0.894</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >降钙素原(ng/mL)</td><td align="center" valign="middle" >0.529</td><td align="center" valign="middle" >0.941</td><td align="center" valign="middle" >0.889</td><td align="center" valign="middle" >0.933</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表5. ROC曲线的Cut-off值分布情况</p><p>将单因素分析有意义的变量带入多因素Logistic回归分析显示：入院CRP、PCT、治疗方式均可作为保守治疗有效率的独立预测因素(表6)。应用R软件，根据其多因素Logistic分析结果构建预测缺血性结肠炎保守治疗有效率的Nomogram模型(图2)，模型显示，随着CRP、PCT水平的下降，IC患者保守治疗的有效率也增加；而在治疗方式中，选择前列地尔联用罂粟碱治疗也可增加IC患者保守治疗的有效率。绘制列线图的校准曲线显示校准曲线和标准曲线具有良好的拟合度，模型的校准能力较好(图3)；在该预测模型绘制的ROC曲线中，AUC = 0.963 (95%CI: 0.928~0.998)大于0.75，说明该模型具有良好的区分度(图4)。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Results of multivariate logistic regression analysis on the effective rate of conservative treatment in patients with I</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >B</th><th align="center" valign="middle" >Wald</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >95%CI</th></tr></thead><tr><td align="center" valign="middle" >白细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.369</td><td align="center" valign="middle" >2.302</td><td align="center" valign="middle" >0.129</td><td align="center" valign="middle" >1.309</td><td align="center" valign="middle" >0.886~2.229</td></tr><tr><td align="center" valign="middle" >中性粒细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.238</td><td align="center" valign="middle" >3.647</td><td align="center" valign="middle" >0.078</td><td align="center" valign="middle" >1.832</td><td align="center" valign="middle" >0.893~3.932</td></tr><tr><td align="center" valign="middle" >中性粒细胞百分比(%)</td><td align="center" valign="middle" >0.217</td><td align="center" valign="middle" >1.932</td><td align="center" valign="middle" >0.217</td><td align="center" valign="middle" >1.287</td><td align="center" valign="middle" >0.824~1.736</td></tr><tr><td align="center" valign="middle" >C-反应蛋白(mg/L)</td><td align="center" valign="middle" >0.031</td><td align="center" valign="middle" >5.246</td><td align="center" valign="middle" >0.022</td><td align="center" valign="middle" >1.031</td><td align="center" valign="middle" >1.004~1.058</td></tr><tr><td align="center" valign="middle" >降钙素原(ng/mL)</td><td align="center" valign="middle" >6.690</td><td align="center" valign="middle" >8.846</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >804.616</td><td align="center" valign="middle" >9.791~6124.597</td></tr><tr><td align="center" valign="middle" >治疗组别(例)</td><td align="center" valign="middle" >2.762</td><td align="center" valign="middle" >4.937</td><td align="center" valign="middle" >0.026</td><td align="center" valign="middle" >0.063</td><td align="center" valign="middle" >0.006~0.722</td></tr></tbody></table></table-wrap><p>表6. 影响IC患者保守治疗有效率的多因素Logistic回归分析结果</p><p>图2. 根据本组患者治疗前血清降钙素原(PCT)、C-反应蛋白(CRP)、治疗方式(“0”代表传统保守治疗，“1”代表传统保守治疗 + 前列地尔联合罂粟碱)构建的IC患者保守治疗有效率的预测模型(Nomogram)，各单项分数相加所得的总分即对应保守治疗的有效率</p><p>图3. 列线图预测模型的校正曲线</p><p>图4. 列线图预测模型区分度的ROC曲线</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>缺血性结肠炎是下消化道出血最常见的病因之一，约占急性下消化道出血住院病人的9%~24% [<xref ref-type="bibr" rid="hanspub.44695-ref9">9</xref>]。在普通人群中，IC的发病率约为4.5/100,000人/年至44/100,000人/年 [<xref ref-type="bibr" rid="hanspub.44695-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref4">4</xref>]。其发病率在近年来呈上升趋势，一方面与患有慢性疾病如动脉粥样硬化性疾病的患者的预期寿命延长密切相关 [<xref ref-type="bibr" rid="hanspub.44695-ref1">1</xref>]，另一方面随着CT、电子结肠镜等辅助检查的普及以及对疾病认识的加深，使得IC的确诊率明显增加 [<xref ref-type="bibr" rid="hanspub.44695-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref7">7</xref>]。现有的研究认为IC主要是由于高血压、高脂血症、糖尿病、高尿酸血症等因素易引起结肠动脉硬化，小血管狭窄、闭塞，使得结肠粘膜动脉供血减少进而导致结肠缺血 [<xref ref-type="bibr" rid="hanspub.44695-ref1">1</xref>]。大多数IC患者可通过保守治疗缓解，不需要手术 [<xref ref-type="bibr" rid="hanspub.44695-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref5">5</xref>]。保守治疗主要包括禁饮食、静脉营养、抗感染、处理原发病、积极对症治疗等方面 [<xref ref-type="bibr" rid="hanspub.44695-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref11">11</xref>]。近年来血管活性药物在IC患者保守治疗中的效果逐渐被认可 [<xref ref-type="bibr" rid="hanspub.44695-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref13">13</xref>]。</p><p>前列地尔是一种血管活性药物，其主要成分为前列腺素，该药物被脂微球载体包裹，不易失活，且具有易于分布到受损血管部位的靶向特性，从而发挥本品扩张血管、抑制血小板聚集的作用 [<xref ref-type="bibr" rid="hanspub.44695-ref14">14</xref>]。前列地尔在治疗慢性动脉闭塞症(血栓闭塞性脉管炎、闭塞性动脉硬化症等)引起的四肢溃疡及微小血管循环障碍引起的四肢静息疼痛，改善心脑血管微循环障碍等方面已有显著效果 [<xref ref-type="bibr" rid="hanspub.44695-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref17">17</xref>]。有报告提出，前列腺素可有效扩张外周血管，增加了结肠血流，缓解IC患者的症状 [<xref ref-type="bibr" rid="hanspub.44695-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref18">18</xref>]。罂粟碱是一种阿片类生物碱，它直接作用于平滑肌细胞，抑制磷酸二酯酶，增加细胞内环磷酸腺苷(CAMP)的浓度，CAMP将血管平滑肌中的酶移出细胞质，产生一个没有神经参与的平滑肌松弛效应 [<xref ref-type="bibr" rid="hanspub.44695-ref19">19</xref>]。该药物多应用于治疗脑、心及外周血管痉挛所致的缺血，以及肾、胆或胃肠道等内脏痉挛 [<xref ref-type="bibr" rid="hanspub.44695-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref20">20</xref>]。近年来罂粟碱在IC患者中的应用逐渐增多 [<xref ref-type="bibr" rid="hanspub.44695-ref13">13</xref>]。但目前有关于前列地尔联用罂粟碱治疗缺血性结肠炎的研究相对较少。在本研究中，前列地尔联合罂粟碱的观察组中IC患者保守治疗的有效率高于对照组，差异有统计学意义(P &lt; 0.05)，且观察组患者症状缓解时间、住院时间、手术率均低于对照组。这与王庆娜等 [<xref ref-type="bibr" rid="hanspub.44695-ref8">8</xref>] 的研究结果一致。然而，一味地保守治疗可能延误手术时机，导致病情恶化，增加死亡率，Joshua Tseng等 [<xref ref-type="bibr" rid="hanspub.44695-ref21">21</xref>] 发现，入院到手术的时间是患者预后不良和死亡的独立危险因素，时间越长，患者预后不良的可能越大；一项包含115位IC行手术治疗患者的研究中，有43人在住院期间死亡，死亡率高达37% [<xref ref-type="bibr" rid="hanspub.44695-ref5">5</xref>]；Nassiba Beghdadi等 [<xref ref-type="bibr" rid="hanspub.44695-ref22">22</xref>] 认为，手术延迟 &gt; 12小时是术后死亡率的独立预测因素。因此，有效地评估保守治疗的效果，可以使病情较重的患者尽早手术治疗，改善患者预后。</p><p>多项研究证实IC患者中WBC水平高于正常人，且与其病情的严重程度呈正相关关系 [<xref ref-type="bibr" rid="hanspub.44695-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref23">23</xref>]。在一项研究中发现，对于接受手术干预的患者来说，较高的白细胞水平是唯一具有统计学意义的变量 [<xref ref-type="bibr" rid="hanspub.44695-ref24">24</xref>]。在本研究中，IC患者入院后的WBC水平在IC患者保守治疗效果中有统计学差异，这与Milluzzo等 [<xref ref-type="bibr" rid="hanspub.44695-ref25">25</xref>] 研究结果一致，他认为WBC和肌酸水平可以作为IC患者预后不良的预测因素，WBC水平越高，病情的严重程度越高，预后不良的风险越大。Montoro Miguel等的研究中单因素分析显示，WBC &gt; 15 &#215; 10<sup>9</sup>/L是IC患者预后不良的影响因素 [<xref ref-type="bibr" rid="hanspub.44695-ref24">24</xref>]。</p><p>有关C-反应蛋白和降钙素原在IC患者预后中的作用的相关报道较少。C-反应蛋白是机体受到感染或组织损伤时血浆中一些急剧上升的蛋白质，CRP可以激活补体和加强吞噬细胞的吞噬而起调理作用，从而清除入侵机体的病原微生物和损伤、坏死、凋亡的组织细胞，IC患者由于肠道血供不足导致肠壁黏膜缺血坏死、肠道菌群紊乱，从而引起CRP的升高。有研究显示，IC患者中CRP水平明显高于普通人 [<xref ref-type="bibr" rid="hanspub.44695-ref23">23</xref>]。本研究发现CRP是IC患者保守治疗效果的独立影响因素，其cut-off值为：56.190，敏感性为94.2%，特异性为76.7%，且患者的CRP水平越低，保守治疗的有效率越高。降钙素原是一种细菌感染后刺激细胞释放的蛋白质，是诊断和检测细菌性感染的一个可靠的参数，已有研究证明了降钙素原在其他炎症性疾病的诊断和评估中的价值 [<xref ref-type="bibr" rid="hanspub.44695-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref27">27</xref>]。Coss&#233; C.等 [<xref ref-type="bibr" rid="hanspub.44695-ref28">28</xref>] 发现，PCT水平与IC患者疾病严重程度呈正相关关系，当PCT ≥ 2 &#181;g/L时，应考虑手术治疗。在本研究中，降钙素原是IC患者保守治疗效果的独立危险因素，其cut-off值为：0.529，具有更高的敏感性(94.1%)和特异性(88.9%)，因此，当患者CRP，PCT水平高于截断值时，可考虑早期手术治疗。</p><p>列线图作为一种简单可视化的图形，使得其在临床中的应用更为方便。列线图多应用于良恶性疾病的预后及疗效的研究中。本研究用多因素分析有意义的三个指标构建Nomogram模型，用以预测IC患者保守治疗的效果。IC患者预后的危险因素已有相关报道，但先前的研究多侧重于并发症方面，如肠道梗阻、腹膜炎均为IC预后不良的独立危险因素 [<xref ref-type="bibr" rid="hanspub.44695-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44695-ref25">25</xref>]，Li等 [<xref ref-type="bibr" rid="hanspub.44695-ref29">29</xref>] 的研究发现中性粒细胞计数是IC患者预后的独立影响因素，并将其纳入预测模型之中。目前，有关CRP、PCT在IC患者预后中的作用却鲜有涉及。本研究构建的列线图模型由患者入院CRP、PCT水平以及治疗方式构成，如果患者CRP、PCT均在本研究ROC曲线所示的最佳截断值水平(表5)，通过模型计算到传统保守治疗的有效率约为0.5~0.6，传统保守治疗 + 联合应用前列地尔和罂粟碱治疗有效率约为0.7~0.8。值得一提的是，该模型仅能评估保守治疗的有效率，而不能完全代表临床决策。对于该模型评估有效率低于0.5且未出现并发症的早期IC患者，可结合临床症状，积极与患者家属沟通风险，酌情手术治疗，改善患者的总体结局。</p><p>本研究存在一定的局限性，首先，该研究是单中心、小样本的研究，缺乏其他中心的数据来印证预测模型的可信度，且无法准确反应总体情况。其次本研究仅采用入院检验结果及治疗一周后的检验结果作为观测指标，不能有效代表疾病的演变。因此有关IC患者保守治疗效果的预测以及前列地尔联合罂粟碱在保守治疗中的应用价值以及CRP、PCT在评估保守治疗效果中的意义仍需要多中心，大样本的研究来进一步证实。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，在IC保守治疗的患者中应用前列地尔联合罂粟碱可有效缩短症状缓解时间和住院时间，增加治疗有效率，改善预后，且无严重不良反应，可在临床中常规应用。入院CRP及PCT水平是治疗有效率的独立影响因素，可用以评估IC患者保守治疗效果，本研究构建的Nomogram模型可实现个体化评估，指导医生和患者选择合理的治疗决策。</p></sec><sec id="s10"><title>文章引用</title><p>张凯凯,柳维林,江秀丽,盛延钦,陈 曦,荆丽宏,刘小雷. 前列地尔联合罂粟碱在IC保守治疗中的临床价值及Nomogram的构建Clinical Value of Alprostadil Combined with Popaverine in Conservative Treatment of Ischemic Colitis and Establishment of a Nomogram Prediction Model[J]. 临床医学进展, 2021, 11(08): 3574-3584. https://doi.org/10.12677/ACM.2021.118522</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44695-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Brandt, L.J., Feuerstadt, P., Longstreth, G.F., et al. (2015) ACG Clinical Guideline: Epidemiology, Risk Factors, Patterns of Presentation, Diagnosis, and Management of Colon Ischemia (CI). The American Journal of Gastroenterology, 110, 18-44. &lt;br&gt;https://doi.org/10.1038/ajg.2014.395</mixed-citation></ref><ref id="hanspub.44695-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Netz, U. and Galandiuk, S. (2017) The Management of Ischemic Colitis. In: Current Surgical Therapy, 12th Edition, Elsevier, Philadelphia, 171-176.</mixed-citation></ref><ref id="hanspub.44695-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yngvadottir, Y., Karlsdottir, B.R., Hreinsson, J.P. and Björnsson, E.S. (2017) The Incidence and Outcome of Ischemic Colitis in a Population-Based Setting. Scandinavian Journal of Gastroenterology, 52, 704-710.  
&lt;br&gt;https://doi.org/10.1080/00365521.2017.1291718</mixed-citation></ref><ref id="hanspub.44695-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Yadav, S., Dave, M., Edakkanambeth, V.J., et al. (2015) A Population-Based Study of Incidence, Risk Factors, Clinical Spectrum, and Outcomes of Ischemic Colitis. Clinical Gastroenterology and Hepatology, 13, 731-8.e1-6.  
&lt;br&gt;https://doi.org/10.1016/j.cgh.2014.07.061</mixed-citation></ref><ref id="hanspub.44695-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Castleberry, A.W., Turley, R.S., Hanna, J.M., et al. (2013) A 10-Year Longitudinal Analysis of Surgical Management for Acute Ischemic Colitis. Journal of Gastrointestinal Surgery, 17, 784-792.  
&lt;br&gt;https://doi.org/10.1007/s11605-012-2117-x</mixed-citation></ref><ref id="hanspub.44695-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chen, M., Remer, E.M., Liu, X.L., et al. (2017) Identification of the Distinguishing Features of Crohn’s Disease and Ischemic Colitis Using Computed Tomographic Enterography. Gastroenterology Report, 5, 219-225.  
&lt;br&gt;https://doi.org/10.1093/gastro/gow037</mixed-citation></ref><ref id="hanspub.44695-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Doulberis, M., Panagopoulos, P., Scherz, S., Dellaporta, E. and Kouklakis, G. (2016) Update on Ischemic Colitis: From Etiopathology to Treatment Including Patients of Intensive Care Unit. Scandinavian Journal of Gastroenterology, 51, 893-902. &lt;br&gt;https://doi.org/10.3109/00365521.2016.1162325</mixed-citation></ref><ref id="hanspub.44695-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王庆娜. 前列地尔联合罂粟碱治疗缺血性结肠炎的临床研究[J]. 临床医药文献电子杂志, 2019, 6(89): 59-60.</mixed-citation></ref><ref id="hanspub.44695-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hreinsson, J.P., Gumundsson, S., Kalaitzakis, E., et al. (2013) Lower Gastrointestinal Bleeding: Incidence, Etiology, and Outcomes in a Population-Based Setting. European Journal of Gastroenterology &amp; Hepatology, 25, 37-43.  
&lt;br&gt;https://doi.org/10.1097/MEG.0b013e32835948e3</mixed-citation></ref><ref id="hanspub.44695-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kruis, W. and Schiff, M. (2020) Combination Treatment with Antibiotics and Glucocorticosteroids for Severe Ischemic Colitis. Digestion, 101, 500-505. &lt;br&gt;https://doi.org/10.1159/000501515</mixed-citation></ref><ref id="hanspub.44695-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Misiakos, E.P., Tsapralis, D., Karatzas, T., et al. (2017) Advents in the Diagnosis and Management of Ischemic Colitis. Frontiers in Surgery, 4, 47. &lt;br&gt;https://doi.org/10.3389/fsurg.2017.00047</mixed-citation></ref><ref id="hanspub.44695-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">马冰, 徐志伟, 张广, 王尚涛. 依达拉奉联合盐酸罂粟碱注射液对重型颅脑损伤病人急性期肠黏膜通透性与血管痉挛的影响[J]. 中西医结合心脑血管病杂志, 2018, 16(16): 2421-2424.</mixed-citation></ref><ref id="hanspub.44695-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">尹小菲, 康文全. 罂粟碱联合丹参川芎嗪治疗缺血性肠炎的疗效分析[J]. 中国实用医药, 2018, 13(23): 103-104.</mixed-citation></ref><ref id="hanspub.44695-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">(2013) Product Information: Prostin VR Pediatric (R) Intravenous Injection Solution, Alprostadil Intravenous Injection Solution. Pharmacia &amp; Upjohn Co. (per DailyMed), New York.</mixed-citation></ref><ref id="hanspub.44695-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, W.F., Dai, J.J., Zheng, X.W., et al. (2021) Myocardial Protective Effect of Intracoronary Administration of Nicorandil and Alprostadil via Targeted Perfusion Microcatheter in Patients Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial. Medicine (Baltimore), 100, e25551.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000025551</mixed-citation></ref><ref id="hanspub.44695-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">阮政文, 江立生, 陈莲. 前列地尔对老年2型糖尿病合并冠心病患者心脏微循环和血清炎性因子水平的影响[J]. 中国老年学杂志, 2020, 40(21): 4531-4533.</mixed-citation></ref><ref id="hanspub.44695-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">何佩. 血栓通联合前列地尔治疗下肢动脉硬化闭塞症的临床研究[J]. 临床医学研究与实践, 2016, 1(6): 4-5.</mixed-citation></ref><ref id="hanspub.44695-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Abe, S., Takayama, T., Ohta, H., et al. (2004) Successful Treatment with Prostaglandin E1 of Ischemic Colitis Complicated by Colonic Stricture. Gastrointestinal Endoscopy, 60, 148-151.  
&lt;br&gt;https://doi.org/10.1016/S0016-5107(04)01526-3</mixed-citation></ref><ref id="hanspub.44695-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">国家药典委员会. 中国药典[M]. 北京: 中国医药科技出版社, 2020: 1088.</mixed-citation></ref><ref id="hanspub.44695-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Guan, S., Liu, Q., Gu, H., et al. (2020) Pluripotent Anti-Inflammatory Immunomodulatory Effects of Papaverine against Cerebral Ischemic-Reperfusion Injury. Journal of Pharmacological Sciences, 144, 69-75.  
&lt;br&gt;https://doi.org/10.1016/j.jphs.2020.07.008</mixed-citation></ref><ref id="hanspub.44695-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Tseng, J., Loper, B., Jain, M., et al. (2017) Predictive Factors of Mortality after Colectomy in Ischemic Colitis: An ACS-NSQIP Database Study. Trauma Surgery &amp; Acute Care Open, 2, e000126.  
&lt;br&gt;https://doi.org/10.1136/tsaco-2017-000126</mixed-citation></ref><ref id="hanspub.44695-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Beghdadi, N., Reitano, E., Cochennec, F., et al. (2020) Predictors of Mortality Following Emergency Open Colectomy for Ischemic Colitis: A Single-Center Experience. World Journal of Emergency Surgery, 15, 40.  
&lt;br&gt;https://doi.org/10.1186/s13017-020-00321-4</mixed-citation></ref><ref id="hanspub.44695-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">赵一晓, 黄坤, 于久飞. 缺血性肠炎发病危险因素及炎症指标相关性分析[J]. 中国中西医结合消化杂志, 2021, 29(2): 105-109.</mixed-citation></ref><ref id="hanspub.44695-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Montoro, M.A., Brandt, L.J., Santolaria, S., et al. (2011) Clinical Patterns and Outcomes of Ischaemic Colitis: Results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE Study). Scandinavian Journal of Gastroenterology, 46, 236-246. &lt;br&gt;https://doi.org/10.3109/00365521.2010.525794</mixed-citation></ref><ref id="hanspub.44695-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Milluzzo, S.M., Correale, L., Marco, G.D., et al. (2021) Leukocytes and Creatinine May Predict Severity and Guide Management of Ischemic Colitis. Annals of Gastroenterology, 34, 202-207. &lt;br&gt;https://doi.org/10.20524/aog.2021.0577</mixed-citation></ref><ref id="hanspub.44695-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Fransvea, P., Covino, M., Rosa, F., et al. (2021) Role of Serum Procalcitonin in Predicting the Surgical Outcomes of Acute Calculous Cholecystitis. Langenbeck’s Archives of Surgery, 1-8.  
&lt;br&gt;https://doi.org/10.1007/s00423-021-02252-3</mixed-citation></ref><ref id="hanspub.44695-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Zhong, Y.H., Yu, Z.Q., Wang, L., et al. (2021) Combined Detection of Procalcitonin, Heparin-Binding Protein, and Interleukin-6 Is a Promising Assay to Diagnose and Predict Acute Pancreatitis. Journal of Clinical Laboratory Analysis, e23869. &lt;br&gt;https://doi.org/10.1002/jcla.23869</mixed-citation></ref><ref id="hanspub.44695-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Cossé, C., Sabbagh, C., Fumery, M., et al. (2017) Serum Procalcitonin Correlates with Colonoscopy Findings and Can Guide Therapeutic Decisions in Postoperative Ischemic Colitis. Digestive and Liver Disease, 49, 286-290.  
&lt;br&gt;https://doi.org/10.1016/j.dld.2016.12.003</mixed-citation></ref><ref id="hanspub.44695-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Li, S., Luo, Y.W., Wang, W., et al. (2021) A Novel Multiparameter Scoring Model for Noninvasive Early Prediction of Ischemic Colitis: A Multicenter, Retrospective, and Real-World Study. Clinical and Translational Gastroenterology, 12, e00370. &lt;br&gt;https://doi.org/10.14309/ctg.0000000000000370</mixed-citation></ref></ref-list></back></article>